Neuroblastomadown arrow

 

Late Effects

 

 

 

 

 

 

 

Home > Disclaimer > Neuroblastoma

 

Neuroblastoma

 

 

Low Risk Category

 

Simplified overview of low risk category NBL and therapy:

NB Even though ANBL0531 had "intermediate risk" in its title, this classification of low risk NBL was developed for this study which is now closed to accrual.

 

Low risk category and therapy:

ANBL0531

Grouping

Criteria used for grouping Therapy
Group 1

INSS Stage 1

Any MYCN status

Any age

 

  • Treated with surgery alone - chemotherapy only for relapse
Group 1

INSS Stage 2A or 2B

> or = 50% resected

Non-MYCN amplified

Any histology

Any DNA Index (DI)

Any age

 

  • Treated with surgery alone - chemotherapy only for relapse
Group 1

INSS Stage 4S

Infant (less than I year old)

Non-MYCN amplified

FH

DI >1

 

  • Appropriate to observe only

Group 2

INSS Stage 2A or 2B

Less than 50% resected

or biopsy only

Non-MYCN amplified

1 - 12 years old

Any histology

Any DI

  • Treated with surgery followed by minimal chemotherapy (2 cycles)
Group 2

INSS Stage 3

Less than I year old

Non-MYCN amplified

FH

DI >1

 

  • Treated with surgery followed by minimal chemotherapy (2 cycles)
Group 2

INSS Stage 3

I - 12 years old

Non-MYCN amplified

FH

  • If 1p loss of heterozygosity (LOH) or unbalanced (unb)-11q LOH then move to intermediate risk category
  • Treated with surgery followed by minimal chemotherapy (2 cycles)
Group 2

INSS Stage 4S

Symptomatic

Infant (less than I year old)

Non-MYCN amplified

FH

DI >1

  • Treat with 2 cycles of chemotherapy

 

Treatment options for low risk NBL may include:

Observation without biopsy:

  • Appropriate for infants younger than 6 months with disease limited to the adrenal gland less than 3cm in diameter.

Surgery:

  • In localized disease, radical surgical excision is the management of choice.
  • Complete or even partial resection alone is usually sufficient therapy.
  • Curative resection is usually possible for Stage 1 disease and sometimes for Stage 2A.
  • Surgery alone can be used to treat biologically favorable and localized tumor which is incompletely resected (stage 2A and stage 2B).

Chemotherapy:

  • In infants with unresectable disease, chemotherapy can downstage the tumor and make excision possible.
  • Used for symptomatic disease or unresectable, progressive disease after surgery
  • Overall survival rate greater than 95%.
  • One course of chemotherapy consists of four 3 week cycles.
  • Each cycle has different combination of 4 drugs:

 

COG clinical trials:

COG-ANBL0531 (therapeutic trial) and COG-ANBL00B1 (biology study required for entry onto COG-ANBL0531):

A risk group classification system was developed for this COG study (see table above). Patients classified as low risk were in treatment Group 1 or Group 2.

Group 1 was treated with surgery followed by observation. Chemotherapy was recommended only for life-threatening or organ-threatening symptoms that could not be relieved by safe surgical resection of the mass. Life-threatening or organ-threatening symptoms included respiratory distress, renal or bowel ischemia, spinal cord compression, gastrointestinal or genitourinary obstruction, and coagulopathy.

Group 2 patients were treated with surgery followed by two cycles of chemotherapy, and if needed additional cycles of chemotherapy until partial response was obtained. If the tumor had 1p or 11q loss of heterozygosity (LOH) or the LOH studies were not performed, the patient was placed in the treatment Group 3 (intermediate risk category) and received four cycles of chemotherapy.

Chemotherapy was given for two cycles (6 weeks) and consisted of moderate doses of carboplatin, cyclophosphamide, doxorubicin, and etoposide. The cumulative dose of each agent was kept low to reduce the risk of late effects, as used in prior COG trials (COG-P9641 and COG-A3961).

RT was reserved for patients with symptomatic life-threatening or organ-threatening tumor that does not respond rapidly enough to chemotherapy and/or surgery.

 

External Link:

Treatment of low risk neuroblastoma at the National Cancer Institute

 

 

Back to top

Next